# Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

> **NCT03517033** · PHASE1 · COMPLETED · sponsor: **Torrent Pharmaceuticals Limited** · enrollment: 30 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Torrent's Nebivolol Tablets
- **DRUG:** Forest Pharmaceuticals Inc.'s Bystolic Tablets

## Key facts

- **NCT ID:** NCT03517033
- **Lead sponsor:** Torrent Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03517033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03517033, "Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03517033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*